Arno Therapeutics, Inc.

ARNI

US0425642032

Pharmaceuticals

Delayed OTC Markets Other stock markets 15:25:51 23/04/2024 BST			5-day change	1st Jan Change
0.0003 ^USD	+417.24%		-.--%	+200.00%

2017	Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	CI
2017	Arno Therapeutics Seeks Acquisitions	CI

Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015

September 11, 2015 at 09:30 pm

On September 4, 2015, Lawrence A. Kenyon, chief operating officer and chief financial officer of Arno Therapeutics, Inc. announced that he is resigning his employment with the company, effective as of September 15, 2015, in order to accept a position with a new employer.

Latest news about Arno Therapeutics, Inc.

Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	25/12/17	CI
Arno Therapeutics Seeks Acquisitions	04/01/17	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	14/11/16	CI
Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC	03/11/16	CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	22/08/16	CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga	16/08/16	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.98 million in funding from a group of investors	14/08/16	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	17/05/16	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	30/03/16	CI
Arno Therapeutics, Inc. Appoints Jay Moorin to its Board of Directors	13/01/16	CI
Arno Therapeutics, Inc. announced that it has received $5.28 million in funding from Commercial Street Capital, LLC, and other investors.	11/01/16	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16/11/15	CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains	21/10/15	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.1 million in funding from Commercial Street Capital, LLC and other investors.	20/10/15	CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12	19/09/15	CI
Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015	11/09/15	CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer	18/08/15	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015	14/08/15	CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12	03/06/15	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	15/05/15	CI
Arno Therapeutics, Inc. Announces Promising Data Supporting the Ongoing Clinical Development Program for Lead Compound Onapristone	13/05/15	CI
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone	07/05/15	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	01/04/15	CI
Arno Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/15	CI
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014	09/12/14	CI

Chart Arno Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
ARNO THERAPEUTICS, INC.	+200.00%	14.8K
CSL LIMITED	-1.62%	90.85B
SAMSUNG BIOLOGICS CO.,LTD.	-0.92%	39.02B
BIOGEN INC.	-10.73%	33.46B
BIOMARIN PHARMACEUTICAL INC.	-19.89%	14.51B
INCYTE CORPORATION	-5.97%	13.22B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.42%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-47.31%	10.57B
SWEDISH ORPHAN BIOVITRUM AB	+6.52%	9.23B
ALTEOGEN INC.	+137.06%	7.71B

Biopharmaceuticals